Umpai Tedrow, DO
Family Medicine · Hickory, NCNPI 1578791513
Payments from drug & device makers
Across 459 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$966
- Otsuka America Pharmaceutical, Inc.$887
- AbbVie$756
- Teva Pharmaceuticals USA, Inc.$519
- Almatica Pharma LLC$447
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,994100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $1,255 |
| Neurocrine Biosciences, Inc. | 48 | $966 |
| Otsuka America Pharmaceutical, Inc. | 52 | $887 |
| AbbVie(2 entities) | 54 | $756 |
| Teva Pharmaceuticals USA, Inc. | 33 | $519 |
| Almatica Pharma LLC | 33 | $447 |
| Alkermes, Inc. | 23 | $415 |
| Johnson & Johnson | 23 | $364 |
| Vanda Pharmaceuticals Inc. | 19 | $364 |
| Noven Therapeutics, LLC | 22 | $319 |
| Lilly USA, LLC | 8 | $230 |
| Indivior Inc. | 13 | $209 |
| Novo Nordisk | 6 | $170 |
| AstraZeneca | 4 | $168 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $100 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Lundbeck LLC | 5 | $89 |
| Corium, LLC | 3 | $70 |
| Eisai Inc. | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
| Luye Pharma (USA) Ltd. | 2 | $52 |
| Amgen | 3 | $52 |
| Tris Pharma Inc | 2 | $29 |
| Bristol Myers Squibb | 1 | $28 |
| Pfizer | 2 | $27 |
| GSK | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Merck | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Noven Pharmaceuticals, Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $11 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,994 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $108,316 |
| JardianceEmpagliflozin | 68 | $69,204 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $62,598 |
| RybelsusSemaglutide | 19 | $50,837 |
| VascepaIcosapent Ethyl | 66 | $33,795 |
| FarxigaDapagliflozin Propanediol | 43 | $33,042 |
| EliquisApixaban | 41 | $32,919 |
| LinzessLinaclotide | 34 | $30,496 |
| XareltoRivaroxaban | 24 | $24,249 |
| Spiriva HandihalerTiotropium Bromide | 35 | $19,877 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $18,915 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $16,709 |
| MounjaroTirzepatide | 15 | $15,631 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,238 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $170 | $159,154112 claims |
| AstraZenecaFarxiga, Symbicort | $168 | $46,28091 claims |
| PfizerEliquis | $27 | $32,91941 claims |
| AbbVieLinzess | $756 | $30,49634 claims |
| Johnson & JohnsonXarelto | $364 | $24,24924 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $22 | $17,67831 claims |
| Lilly USA, LLCMounjaro | $230 | $15,63115 claims |
| BayerKerendia | $20 | $9,17513 claims |
| MerckDulera | $14 | $4,14112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Hickory
- Jonathan WilsonHickory$12.7M
- John EarlHickory$4.7M
- Scott PolsterHickory$2.6M
- Robert HartHickory$636K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.